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Abstract
Background: Iron deficiency anaemia in pregnancy (IDAP) affects 11–18% of Australian pregnancies and is
associated with adverse perinatal outcomes. National prescribing data suggests the use of intravenous iron in
pregnancy is increasingly common. This study aimed to: 1) Establish the current patterns of intravenous iron use by
Fellows of the Royal Australian and New Zealand College of Obstetricians (FRANZCOG) when treating iron
deficiency and IDAP including immediately postpartum and; 2) Assess FRANZCOG opinions regarding potential trial
of intravenous iron for first-line treatment of IDAP.
Methods: An online survey of RANZCOG Fellows practicing obstetrics was distributed in September 2018. Results
were analysed descriptively and responses compared by clinician demographics using Chi-squared testing.
Results: Of 484 respondents (21% of FRANZCOG), 457 were currently practicing obstetrics. Most prescribed
intravenous iron in pregnancy (96%) and/or postpartum (85%). Most intravenous iron was prescribed for IDAP (98%)
rather than iron deficiency without anaemia (53%), and for IDAP most commonly second-line to failed oral iron
supplementation and first-line in special circumstances (59%). Intravenous iron prescribing was associated with
shorter time since FRANZCOG completion (p = 0.01), public hospital practice (p = 0.008) and higher hospital birth
numbers (p = 0.01). Most respondents (90%) would consider a randomised controlled trial of first-line intravenous
iron for IDAP, although views on appropriate thresholds differed.
Conclusions: Almost all respondents prescribed intravenous iron for IDAP, and while mostly used for second-line
treatment over half sometimes used it first-line. With accelerating intravenous iron use, further research is required
into its optimal use in pregnancy, recognizing important clinical outcomes and cost effectiveness.
Background
The prevalence of iron deficiency anaemia in pregnancy
(IDAP) is estimated to be 20% globally [1] and 11–18% in
Australia [2, 3]. All-cause severe anaemia is associated
with increased maternal risks of blood transfusion, pro-
longed hospitalisation and maternal mortality [4, 5],
alongside increased infant risks of perinatal death, small
for gestational age and premature delivery [6, 7]. Given
these associations the importance of treating IDAP is gen-
erally well accepted, despite limited quality data on the
correlation between treatment and clinical outcomes [8].
The treatment of iron deficiency (ID) in pregnancy,
with or without anaemia, has undergone significant
shifts recently. This is multifactorial, including more
screening and hence greater diagnosis of ID, the intro-
duction of newer intravenous iron preparations [9] and
increased recognition of the importance of patient blood
management with new national guidelines [10]. Current
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Australian maternity guidelines recommend oral iron
supplementation as first-line treatment for IDAP, as a
‘Grade B’ recommendation reflecting sufficient quality
literature to guide practice in most situations. However,
10–40% of women taking oral iron experience significant
gastrointestinal adverse effects, negatively impacting ad-
herence [2]. Indeed, in a recent survey of Australian
women, of those with oral iron adverse effects, 20%
ceased supplements before course completion (unpub-
lished observations). For this reason, Australian guide-
lines have recently been updated to recommend either
lower dose or intermittent dosing of oral iron supple-
mentation to improve tolerability.
Australian antenatal care guideline recommend intra-
venous iron when there is poor response to or inability
to comply with oral therapy [11]. Additionally, Austra-
lian patient blood management guidelines recommend
intravenous iron first-line when “rapid restoration … is
required”, such as when delivery is imminent [10].
Rates of intravenous iron use more than doubled in
Australian women of reproductive age between 2014
and 2017 [9, 12] which has been attributed to greater
recognition of the adverse effects of oral iron and the
“ease” of intravenous iron administration [13]. A recent
meta-analysis suggests there may be a decreased need
for blood transfusion in women treated with intravenous
versus oral iron for IDAP, however the quality of the evi-
dence was rated as low [14] with many studies of poor
quality and not measuring important clinical outcomes
[15]. Furthermore, intravenous iron has cost implica-
tions [12], is infrequently associated with serious adverse
effects, including major allergic reactions in 3.6/1000
women [16] and carries a risk of skin staining that has
led to a number of notifications to medical defence orga-
nisations in Australia [17].
The increased use of intravenous iron in Australia
warrants a better understanding of current perinatal pre-
scribing practices. This study therefore aimed to identify
the current knowledge, attitudes and behaviours regard-
ing intravenous iron prescription of fellows of the Royal
Australian and New Zealand College of Obstetricians
and Gynaecologists (RANZCOG) including indications
for intravenous iron, frequency of prescribing, perceived
advantages and disadvantages, and theoretical accept-
ability of a randomised trial of intravenous iron for first-
line IDAP treatment.
Methods
An anonymous survey of Fellows of the Royal Australian
and New Zealand College of Obstetricians and Gynae-
cologists (FRANZCOG) was undertaken in September
2018. The online survey (Appendix 1) was emailed by
the RANZCOG to all Fellows (n = 2275), using the on-
line platform SurveyMonkey™. A follow-up reminder was
sent after 2 weeks and the survey was closed after 6
weeks.
Eligible clinicians were FRANZCOGs currently work-
ing in the field of obstetrics or both obstetrics and gy-
naecology. FRANZCOGs who stated they were only
working in gynaecology were directed to survey exit and
not included in analysis. Survey completion was taken to
indicate consent.
Clinician demographic questions included practice
duration, region, setting and births/annum. Questions
on intravenous iron prescribing focused on the setting,
including respectively: a) IDAP: gestation, circumstances
under which intravenous iron was prescribed, advan-
tages and disadvantages; b) ID without anaemia in preg-
nancy: gestation and indication; c) Postpartum: use of
intravenous iron. Thresholds for inclusion in a theoret-
ical future randomised controlled trial (RCT) of first-line
intravenous iron in pregnancy in the second or third tri-
mester were also identified.
Statistical analysis was performed using IBM SPSS Sta-
tistics 25 (IBM SPSS Statistics 25 for Windows, IBM
Corporation, Armonk, NY). Descriptive analysis of
demographic characteristics included frequency and per-
centage tabulation while free text responses were ana-
lysed using common theme examination. Association
between intravenous iron prescribing in pregnancy and
clinician demographics was assessed, including time
since obtaining FRANZCOG, practice area, setting and
number of births. Similarly, association between clinician
subgroups including practice setting and duration of
FRANZCOG with IDAP and ID without anaemia treat-
ment approaches, was assessed using either Pearsons’
Chi-Squared or Fisher’s Exact tests where appropriate.
Ethical approval was granted by the Human Research
Ethics Committee of the South Eastern Sydney Local
Health District (SESLHD HREC 16/371).
Results
Overall, 484 fellows responded to the survey (response
rate = 21%), of whom the majority were obstetricians
and gynaecologists (n = 388) or obstetricians alone (n =
69). The small minority who practiced solely as gynae-
cologists (n = 27) were excluded from all further ana-
lyses. Most clinicians practiced in New South Wales
(26%), Victoria (21%) or Queensland (19%), with the ma-
jority working in metropolitan centres (public n = 239,
private n = 170) (Table 1).
Intravenous iron prescribing
Almost all respondents indicated they prescribe intra-
venous iron in pregnancy (96%) and/or postpartum
(85%), with administration predominantly hospital-based
(92%) (Table 2). A third of clinicians prescribed fewer
than 10 infusions per annum (31%), while a quarter
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Table 1 Clinician Demographics
Frequency (n) Percentage (%)
Clinician type (n = 457)
Obstetricians 69 15.1
Both obstetricians and gynaecologists 388 84.9
Time since obtaining FRANZCOG or overseas equivalent (n = 444)
< 5 years 104 23.4
5–9 years 74 16.7
10–19 years 115 25.9
20 years or more 148 33.3
Prefer not to say 3 0.7
Area of practice (n = 444)
New South Wales 116 26.1
Victoria 91 20.5
Queensland 83 18.7
Western Australia 42 9.5
North Island New Zealand 35 7.9
South Australia 30 6.8
South Island New Zealand 19 4.3
Tasmania 10 2.3
Australian Capital Territory 8 1.8
Prefer not to say 6 1.4
Northern Territory 4 0.9
Practice setting (n = 444)a
Metropolitan public hospital 239 53.8
Metropolitan private hospital 170 38.3
Non-metropolitan public hospital 107 24.1
Non-metropolitan private hospital 33 7.4
Prefer not to say 3 0.7
Otherb 3 0.7
Births per annum in largest hospital of practice (n = 444)
< 1000 73 16.4
1000–2499 119 26.8
2500–3999 106 23.9
4000 or more 146 32.9
Number of women with IDAP treated per annum (n = 419)
< 10 42 10.0
10–24 108 25.8
25–49 99 23.6
≥ 50 141 33.7
Not sure 29 6.9
Number of women with ID without anaemia treated per annum (n = 413)
< 10 70 16.9
10–24 91 22.0
25–49 65 15.7
≥ 50 136 32.9
Not sure 51 12.3
Abbreviations: FRANZCOG Fellowship of Royal Australian and New Zealand College of Obstetricians and Gynaecologists; IDAP iron-deficiency anaemia in
pregnancy; ID, iron deficiency
aAble to select multiple practice settings
bOther practice settings (n = 3) included country practice, academia and private practice
Smith-Wade et al. BMC Pregnancy and Childbirth          (2020) 20:665 Page 3 of 11
prescribed 10–19 (25%) or 30 or more (23%) infusions
per year. The most commonly prescribed formulation
was ferric carboxymaltose (FCM) (90%). Intravenous
iron was mostly prescribed in the third trimester, al-
though a minority prescribed it in the first trimester (8%
for IDAP, 3% for ID only).
Overall differences in prescribing practices were small.
Those who had obtained their FRANZCOG or overseas
equivalent < 10 years ago were more likely to prescribe
intravenous iron (100% vs 94% with FRANZCOG ≥10
years, P = 0.02), as were those practicing in public hospi-
tals (97% vs 91% for those who were not, P = 0.008) and
in hospitals with birth numbers > 2500/annum (98% vs
93% with < 2500/annum, P = 0.01) (Table 3).
Perceived advantages of intravenous iron in pregnancy
included improvement of iron status parameters in those
with poor oral iron tolerance (92%) and adherence
(76%), late pregnancy IDAP or special circumstances
Table 2 Intravenous iron prescribing practices
Question (n = number of responses) Frequency (n) Percentage (%)
Prescribe IV iron in pregnancy (n = 444)
Yes 426 95.9
No 18 4.1
Prescribe IV iron postpartum (n = 429)
Yes 364 84.8
No 65 15.2




Number of infusions prescribed in pregnancy and/or postpartum per annum (n = 425)
< 10 132 31.1
10–19 107 25.2
20–29 80 18.8
30 or more 97 22.8
Don’t prescribe 9 2.1
IV preparation prescribed (n = 425)a
Ferric carboxymaltose (Ferinject) 381 89.6
Iron polymaltose (Ferrosig, Ferrum-H) 54 12.7
Don’t know 16 3.8
Iron sucrose (Venofer) 11 2.6
Othera 7 1.6
Gestation range of IV iron prescribing in IDAP (n = 419)b
Prescribe during pregnancy 410 97.9
< 13 weeks 35 8.4
13–27 weeks 145 34.6
≥ 28 weeks 406 96.9
Do not prescribe in pregnancy 9 2.1
Gestation range of IV iron prescribing in pregnancy for ID without anaemia (n = 413)7
Prescribe during pregnancy 220 53.3
< 13 weeks 14 3.4
13–27 weeks 51 12.3
≥ 28 weeks 220 53.3
Do not prescribe 193 46.7
Abbreviations: IV intravenous; IDAP iron deficiency anaemia in pregnancy; ID iron deficiency. Superscript: F Fisher’s Exact; C Pearson’s Chi-Squared
aNil alternative infusions specified
bParticipants could select multiple ranges
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(76%), and its rapid improvement of iron status parame-
ters (60%). Among ‘other’ advantages specified were spe-
cific difficulties of oral iron use (n = 6), the avoidance of
blood transfusion (n = 4), improvement of iron stores
following postpartum haemorrhage (PPH) (n = 3), re-
duced PPH risk (n = 1) and maternal QOL outcomes
(n = 1) (Table 4).
Disadvantages identified by clinicians included ma-
ternal adverse outcomes (58%), requirement for
venepuncture (57%), practical difficulties of adminis-
tration (44%) and high cost to the health service
(31%). ‘Other’ commonly identified disadvantages in-
cluded the risk of anaphylaxis (n = 18), risk of aller-
gic reactions (n = 10) and other adverse effects (n =
12) (Table 4).
The principal treatment approach for IDAP was ‘oral
iron usually first-line therapy, intravenous iron may be
used as first-line therapy in special circumstances, and
intravenous iron always used as second-line therapy if
first-line oral iron fails’ (59%). For ID without anaemia,
the predominant treatment approach stated by respon-
dents was ‘oral iron always as first-line therapy, intraven-
ous iron may be used as second-line therapy in certain
circumstances (e.g. patient intolerant of oral iron and
still iron deficient late in pregnancy)’ (46%) (Fig. 1).
There were no differences in approach to the treatment
of IDAP or ID without anaemia in pregnancy by
clinicians in private practice compared to public practice
(Table 5).
Reasons for prescribing intravenous iron for ID with-
out anaemia in pregnancy included intolerance of oral
iron (44%), women identifying as Jehovah’s witness
(32%), high bleeding risk (31%) and convenience (5%).
Common theme analysis of ‘other’ reasons (n = 29), indi-
cated importance of symptoms including extreme mater-
nal fatigue (Table 4). Forty-three percent of clinicians
(n = 178) stated they do not prescribe intravenous iron
in this context.
Common indications for the use of intravenous iron
postpartum included presence of symptoms (68%), oral
iron intolerance (51%), special circumstances such as Je-
hovah’s witness (50%), and likely oral iron nonadherence
post-discharge (43%). Where clinicians indicated that
they only prescribe intravenous iron postpartum below a
certain haemoglobin threshold (58%), of those that spe-
cified levels these included < 70 g/L (n = 5), < 80 g/L (n =
16), < 90 g/L (n = 26) with one clinician additionally spe-
cifying acute bleed, < 100 g/L (n = 21) with additional
specifiers including postpartum haemorrhage and other
symptoms, < 110 g/L (n = 1) and < 115 g/L (n = 1).
Thresholds for theoretical trial inclusion
Most clinicians (90%) would consider a theoretical ran-
domised trial as an option. Inclusion thresholds for a





IV iron prescribing in pregnancy (n, %)a P-value
Yes No
Time since obtaining FRANZCOG or overseas equivalent (n = 441)
< 10 years 178 (40.4) 176 (98.9) 2 (1.1) 0.014C*
≥ 10 years 263 (59.6) 248 (94.3) 15 (5.7)
Area of practice (n = 438)
Australia 384 (87.7) 368 (95.8) 16 (4.2) 0.707F
New Zealand 54 (12.3) 53 (98.1) 1 (1.9)
Practice setting (n = 441)
Metropolitanb 323 (73.2) 310 (96.0) 13 (4.0) 1.000F
Non-metropolitan 118 (26.8) 113 (95.8) 5 (4.2)
Publicc 342 (77.6) 333 (97.4) 9 (2.6) 0.008F**
Not public 99 (22.4) 90 (90.9) 9 (9.1)
Births per annum in largest hospital of practice (n = 444)
< 2500 192 (43.2) 179 (93.2) 13 (6.8) 0.011C***
> 2500 252 (56.8) 247 (98.0) 5 (2.0)
Abbreviations: IV intravenous; FRANZCOG Fellowship of Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Superscript: F, Fisher’s
Exact; C, Pearson’s Chi-Squared
an = 444
b“Metropolitan” represents clinicians whose practice sites include metropolitan public and/or metropolitan private hospitals; “non-metropolitan” includes clinicians
who practice exclusively in non-metropolitan public hospitals, non-metropolitan private hospitals or others
c“Public” represents clinicians whose practice sites include metropolitan public and/or non-metropolitan public hospitals; “not public” includes clinicians who
practice exclusively in metropolitan private hospitals, non-metropolitan private hospitals or others
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Table 4 Free text responses
Common themes Representative responses
Advantages of IV iron
Specific difficulties with oral iron (n = 6) Low ferritin, not responding to oral iron
Avoid side effects of oral iron
Noncompliance with oral iron
Avoids the daily hassle of taking oral tabs
Avoidance of blood transfusion (n = 4) Reduction in need for transfusion peri-partum
Well timed, it can be a step to consider before packed RBCs transfusion, although this consideration has
more merit in the immediate postpartum period
Useful after a mild postpartum haemorrhage
Postpartum haemorrhage when Hb is between 7 and 9
Reduced PPH risk (n = 1) Women bleed less at delivery
Maternal QOL outcomes (n = 1) Health related QOL outcomes https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488743/
Others (n = 8) Although NOT in favour of infusion, hospital dictates one to implement infusion
Symptomatic women
You know the iron status will improve
Severe iron deficiency
Disadvantages of IV iron
Anaphylaxis (n = 18) Risk of anaphylaxis (although low)
Anaphylaxis 1/1000 = risk to mother and baby
Other adverse effects (n = 12) Potential side effects
Adverse reactions in up to 20%
Risk of allergic reactions (n = 10) Possibility of allergic reactions
Risk of allergic and anaphylactoid events not inconsiderable and overall adverse reactions - a few/100
Administrative difficulties (n = 4) Tedious process to prescribe. Too much admin for clinic
Cost and resource factors (n = 4) Cost of (hospital) admission to administer the drug
Cost to health services and personal needed
Over-prescription (n = 3) Over prescribed, e.g. women with low serum iron but normal Hb
It’s often not necessary
Lack of evidence regarding improved
pregnancy outcomes (n = 2)
Lack of evidence on its efficacy
No evidence of improved outcome of pregnancy; possible increased adverse outcome
Others (n = 7) Minimal disadvantages - a few have reactions, mainly fever but not seen major adverse effects
Most women prefer it compared to side effects of oral iron
Risks of toxicity, huge doses used are above physiological, risks of free radical generation
Indications for IV iron in the treatment of iron deficiency without anaemia
Symptomatic iron deficiency (n = 9) Extreme tiredness after other options tried
Very rarely if restless legs or severe fatigue if not tolerating oral supplementation
Special circumstances (n = 4) Hyperemesis with PICC (peripherally inserted central) line, influenza or bronchitis, bowel disease
I would only do this where a woman was unable to access regular antenatal care … and where oral iron
was not well tolerated.
Intolerance to oral iron in a Jehovah’s witness with a high bleeding risk
Not used (n = 4) I have recently modified my practice so that the target is Hb not ferritin. I therefore … modify oral iron
supplements … and actively try to avoid IV infusions of iron
In my institution I do not prescribe, but many others do
Women’s preference (n = 3) Women prefer it. Most of the women I see dislike oral replacement and avoid secondary to sides effects, i.e.
constipation, nausea
Patient request
Response to oral iron (n = 3) Failure of oral iron supplements with falling Hb AND altered RBC indices
Lack of response to oral iron
Precaution in case of PPH (n = 2) To increase iron store as a precaution against PPH
Other (n = 4) Only on the advice of obstetric medicine colleagues
Iron deficiency (with or without anaemia) is a condition that requires treatment.
Aim for normal iron stores in fetus
Would consider on case by case. Wouldn’t routinely measure iron unless anaemic or if notable drop over
successive trimesters.
Abbreviations: IV intravenous; RBC red blood cell; PPH postpartum haemorrhage; Hb haemoglobin; QOL quality of life
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theoretical RCT of first-line oral iron versus intravenous
iron in pregnancy in order of acceptability were IDAP
with Hb < 100 g/L (54%), IDAP with any Hb threshold
in the presence of special circumstances (47%), followed
by IDAP with Hb < 90 g/L (36%) and ID with Ferritin <
15 μg/L (35%) (Table 6). Identifying IDAP with any level
Hb as an appropriate threshold for inclusion was associ-
ated with public practice setting (P = 0.04), while per-
ceiving that the trial was not an option was associated
with longer FRANZCOG duration (P = 0.009).
Discussion
This survey is the best available representation of
current practice towards treatment of ID in pregnancy
by specialist obstetricians in Australia and New Zealand.
Given that over three quarters of obstetricians surveyed
work in public hospitals, these findings may be extrapo-
lated to public hospitals. There are high rates of intra-
venous iron use by obstetricians in Australia and New
Zealand for ID and IDAP, predominantly in hospital set-
tings and most commonly in later gestation. While
around half of obstetricians prescribe < 20 infusions per
annum, almost a quarter prescribe 30 or more infusions
a year. Interestingly, 8% of clinicians stated they pre-
scribed intravenous iron in the first trimester for either
IDAP and/or ID without anaemia, despite this being
contraindicated [18].
The key point highlighted by our findings is that the
prescribing of FRANZCOGs for the treatment of ID in
pregnancy is not consistent with Australian antenatal
care guidelines or patient blood management guide-
lines [1, 10, 11] There is an appropriate differentiation
between IDAP and ID without anaemia in pregnancy,
acknowledging the evidence of increased risk of adverse
maternal and fetal outcomes with maternal anaemia [4,
5, 7]. Nonetheless, intravenous iron is commonly pre-
scribed for women with ID without anaemia, a shift in
practice that has been well recognised recently. This sur-
vey highlights that some instances of use in this cohort
are established indications, for example women identify-
ing as Jehovah’s witness or of high bleeding risk [10],
however convenience (5%), poor tolerance of oral iron
and severity of maternal symptoms as indications for use
represent a clear departure between recommendations
and practice [11]. This may be interpreted as failure to
capture this shift in clinicians views’ or alternately that
this reiterates the lack of quality clinical outcomes data,
resulting in heterogenous practice. Irrespective, increas-
ingly liberal use of intravenous iron may overlook the
potential risk of serious, albeit uncommon side effects
such as anaphylaxis and permanent skin tattooing [14],
particularly in settings with less rigorous benefit data.
Additionally, it must be noted that the fetal safety of
intravenous iron remains unclear. It has been postulated
that delivering large iron loads over a short time period
in intravenous infusions, may increase the risk of iron
free radicals inducing oxidative damage to vulnerable
placental tissues [19, 20].
Intravenous iron unequivocally improves haemato-
logical parameters, with a recent meta-analysis finding a
mean difference in maternal haemoglobin of 0.85 g/L
and ferritin of 63.3μg/L [14]. However, clinical outcome
data such as quality of life (QOL), breast feeding rates,
preterm birth and postnatal depression was not well
Fig. 1 Treatment approach to iron deficiency anaemia in pregnancy (IDAP) and iron deficiency (ID) without anaemia
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reported in the studies included in this meta-analysis,
many of which were undertaken in low and middle in-
come countries. The 2011 Cochrane review identified
the need for assessment of clinical outcomes and effects
of treatments of IDAP in large, quality randomised trials
[8]. Secondary endpoints of a recent Australian RCT for
IDAP comparing intravenous FCM, intravenous poly-
maltose (IPM) and oral iron sulphate (IS) found that
higher overall serum ferritin was associated with an im-
provement in QOL [21]. Findings of this study are diffi-
cult to interpret given the association between QOL
improvement and intravenous iron was indirect; QOL
was improved with higher overall serum ferritin, which
was achieved in groups of women receiving intravenous
iron. Similarly, an international multi-centre RCT com-
paring first-line FCM and oral IS demonstrated that
improved pre-delivery vitality scores and social function-
ing were significantly associated with FCM [22]. Both
studies are biased by their open-label nature, a major
limitation given QOL measures are self-reported. Add-
itionally, the latter study was sponsored by a pharma-
ceutical company. Without substantial evidence of
clinical superiority of intravenous iron, its use in first-
line treatment of IDAP and ID highlights the importance
of addressing non-evidence based treatment trends be-
fore they become common practice [9].
FCM was the most commonly used intravenous prep-
aration, consistent with its favourable safety profile with
moderate or severe ADRs occurring in the realm of 3.6/
1000 for FCM versus 14.0/1000 for IPM and 7.9/1000
for IS [16]. FCM also has a shorter infusion time than
IPM so may have lower administration (nursing) costs





Practice setting (n) and percentage (%)b,c p-
valuePublic Not public
Oral iron always first-line, IV possibly second-line
IDAP Yes 141 (33.9) 112 (79.4) 29 (20.6) 0.705C
No 275 (66.1) 214 (77.8) 61 (22.2)
ID without anaemia Yes 188 (45.9) 148 (78.7) 40 (21.3) 0.846C
No 222 (54.1) 173 (77.9) 49 (22.1)
Oral usually first-line, IV sometimes first-line and always second-line
IDAP Yes 247 (59.4) 192 (77.7) 55 (22.3) 0.705C
No 169 (40.6) 134 (79.3) 35 (20.7)
ID without anaemia Yes 91 (22.2) 65 (71.4) 26 (28.5) 0.072C
No 319 (77.8) 256 (80.3) 63 (19.7)
IV usually first-line
IDAP Yes 3 (0.7) 3 (100) 0 (0) 1.000F
No 413 (99.3) 323 (78.2) 90 (21.8)
ID without anaemia Yes 2 (0.5) 2 (100) 0 (0) 1.000F
No 408 (99.5) 319 (78.2) 89 (21.8)
IV never
IDAP Yes 1 (0.2) 1 (100)) 0 (0) 1.000F
No 415 (99.8) 325 (78.3) 90 (21.7)
ID without anaemia Yes 68 (16.6) 55 (80.9) 13 (19.1) 0.571C
No 342 (83.4) 266 (77.8) 76 (22.2)
No consistent policy
IDAP Yes 19 (4.6) 14 (73.7) 5 (26.3) 0.575C
No 397 (95.4) 312 (78.6) 85 (21.4)
ID without anaemia Yes 47 (11.5) 38 (80.9) 9 (19.1) 0.651C
No 363 (88.5) 283 (78.0) 80 (22.0)
Abbreviations: IV intravenous; IDAP iron deficiency anaemia in pregnancy; ID iron deficiency. Superscript: F, Fisher’s Exact; C, Pearson’s Chi-Squared
aFor IDAP n = 416; For ID without anaemia n = 413
bFor practice setting analysis IDAP n = 416, ID without anaemia n = 410
c“Public” represents clinicians whose practice sites include metropolitan public and/or non-metropolitan public hospitals; “not public” includes clinicians who
practice exclusively in metropolitan private hospitals, non-metropolitan private hospitals or others
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for outpatients, despite the preparation itself being more
costly [14, 21]. FCM was listed on the Australian
Pharmaceutical Benefits Scheme in 2014 and the New
Zealand Pharmaceutical Management Agency in 2017,
the former to which Seeho et al., (2018) largely attributes
the rise in intravenous iron use [9]. Our findings also
support the significant healthcare burden of ID with or
without anaemia in pregnancy, with roughly one third of
respondents treating at least fifty women per annum
with IDAP (34%) and ID without anaemia (33%).
Oral iron intolerance was stated as a reason for
intravenous iron prescription by some obstetricians.
Although oral iron treatment strategies were not ad-
dressed in this survey, it is important to highlight the
recently recognised role of ‘risk mitigation’ strategies
used to improve tolerance and compliance, including
reduced dose elemental iron, intermittent dosing, and
avoidance of twice daily dosing [13]. The recently
published British Society of Haematology guidelines
outline the strategies that can be used to reduce
symptoms of oral iron and lead to improve
compliance and hence correction of iron deficiency
anaemia [20].
The findings from our study support the acceptance of
a potential RCT for firstline use of intravenous iron in
pregnancy for IDAP (not ID alone) with a haemoglobin
cut off of 100 g/L, where most clinicians would consider
including their patients. While the lack of universal cut-
offs for haematological measures of iron status in preg-
nancy is recognised as a research need [23], lowering in-
clusion thresholds could meaningfully reduce a potential
IDAP study cohort in an Australian and New Zealand
setting, where severe IDAP is uncommon. Indeed, Kha-
lafallah et al’s recent Australian RCT used a haemoglo-
bin threshold extending to ≤120 g/L, well above IDAP
thresholds defined by Australian guidelines and those
deemed acceptable by our cohort [21]. As such, under-
standing factors impacting a potential trial of first-line
intravenous versus oral iron for IDAP is critical to en-
suring a future study utilises appropriate and feasible in-
clusion thresholds and measures clinical outcomes that
will meaningfully inform practice.
Table 6 Inclusion thresholds for theoretical trial and association with practice setting and FRANZCOG Duration








Time since obtaining FRANZCOG (n)
and percentage (%)
p-value
Public Not public < 10 years > 10 years
IDAP
Any Hb Yes 114 (26.6) 79 (69.9) 34 (30.1) 0.038C* 50 (43.9) 64 (56.1) 0.243C
No 314 (73.4) 248 (79.5) 64 (20.5) 117 (37.6) 194 (62.4)
Hb < 100 g/L Yes 232 (54.2) 177 (77.0) 53 (23.0) 0.993C 97 (42.0) 134 (58.0) 0.214C
No 196 (45.8) 150 (76.9) 45 (23.1) 70 (36.1) 124 (63.9)
Hb < 90 g/L Yes 155 (36.2) 116 (75.8) 37 (24.2) 0.680C 57 (36.8) 98 (63.2) 0.420C
No 273 (63.8) 211 (77.6) 61 (22.2) 110 (40.7) 160 (59.3)
Hb < 80 g/L Yes 140 (32.7) 105 (76.1) 33 (23.9) 0.772C 51 (36.3) 89 (63.6) 0.397C
No 288 (67.3) 222 (77.4) 65 (22.6) 116 (40.7) 169 (59.3)
Any Hb in special circumstancesb Yes 202 (47.2) 158 (78.6) 43 (21.4) 0.440C 78 (38.3) 123 (61.2) 0.845C
No 226 (52.8) 169 (75.4) 55 (24.6) 89 (39.7) 135 (60.3)
ID without anaemia
Ferritin < 30 μg/L Yes 42 (9.8) 29 (69.0) 13 (31.0) 0.201C 20 (47.6) 22 (52.4) 0.245C
No 386 (90.2) 298 (77.8) 85 (22.2) 147 (38.4) 236 (61.6)
Ferritin < 15 μg/L Yes 151 (35.3) 116 (76.8) 35 (23.2) 0.965C 55 (36.7) 95 (63.3) 0.413C
No 277 (64.7) 211 (77.0) 63 (23.0) 112 (40.7) 163 (59.3)
Trial not an option Yes 45 (10.5) 34 (77.3) 10 (22.7) 0.956C 9 (20.9) 34 (79.1) 0.009C**
No 383 (89.5) 293 (76.9) 88 (23.1) 158 (41.4) 224 (58.6)
Other Yes 20 (4.7) 16 (80.0) 4 (20.0) 1.000F 5 (25.0) 15 (75.0) 0.180C
No 408 (95.3) 311 (76.8) 94 (23.2) 162 (40.0) 243 (60.0)
Abbreviations: FRANZCOG Fellowship of Royal Australian and New Zealand College of Obstetricians and Gynaecologists; IDAP iron deficiency anaemia in
pregnancy; ID iron deficiency; Hb haemoglobin. Superscript: F, Fisher’s Exact; C, Pearson’s Chi-Squared
a“Public” represents clinicians whose practice sites include metropolitan public and/or non-metropolitan public hospitals; “not public” includes clinicians who
practice exclusively in metropolitan private hospitals, non-metropolitan private hospitals or others
bExamples of special circumstances specified included late in pregnancy, Jehovah’s witness, known prior oral iron intolerance
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Limitations of this study
Strengths of this study include that it reflects current
practice by specialist obstetricians in Australia and New
Zealand in both urban and metropolitan areas. Our
study was limited by the low response rate, however this
was comparable to similar studies of the RANZCOG
membership of 19–23%, and still represents a sizeable
cohort [24, 25]. Nonetheless, potential self-selection bias
must be acknowledged as a limitation, particularly in
light of this response rate; as with any survey, those that
have greater interest or more strongly held views on a
topic may be more inclined to complete the survey. An-
other perceived limitation may be that this survey failed
to capture the views of other health care professionals
involved in antenatal care, particularly general practi-
tioners who are responsible for up to 50% of intravenous
iron prescribing for women of reproductive age [12].
However, although Australian national prescribing data
does not provide a breakdown on intravenous iron pre-
scribing in pregnancy versus non-pregnant reproductive-
age women, our observational experience is that general
practitioners are reluctant to administer intravenous iron
in pregnancy outside the hospital setting, and so likely
represent a small proportion of intravenous iron pre-
scribers in pregnancy. Obstetric physicians in tertiary
centres are another important prescribing group not
captured by this survey, although this speciality group
has few practicing members in Australia. That being
said, the rationale for restricting the survey population
to FRANZCOGs alone was to establish the consensus
among obstetricians regarding ID treatment, as those
most likely to influence local policy and to be involved
in a potential trial.
Conclusions
Many obstetricians in Australia and New Zealand pre-
scribe intravenous iron for IDAP, while half prescribe it
for ID without anaemia. Adherence to national guide-
lines regarding use of intravenous iron appeared sub-
optimal. Further research is required into the optimal
treatment of IDAP and ID without anaemia in antenatal
and postnatal settings, particularly establishing import-
ant clinical outcomes. It is therefore encouraging that a
prospective RCT was acceptable to most clinicians.
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